[1]何晨,综述,袁晋青,等.冠状动脉支架置入术后再狭窄的治疗研究进展[J].心血管病学进展,2016,(4):350-353.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.006]
 HE Chen,YUAN Jinqing.Current Treatment of In-stent Restenosis[J].Advances in Cardiovascular Diseases,2016,(4):350-353.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.006]
点击复制

冠状动脉支架置入术后再狭窄的治疗研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年4期
页码:
350-353
栏目:
综述
出版日期:
2016-08-15

文章信息/Info

Title:
Current Treatment of In-stent Restenosis
作者:
何晨综述袁晋青审校
北京协和医学院 中国医学科学院 国家心血管病中心 阜外医院心血管内科,北京 100037
Author(s):
HE ChenYUAN Jinqing
Department of Cardiology, Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Science & PekingUnion Medical College, Beijing 100037, China
关键词:
药物洗脱支架 经皮冠状动脉介入治疗 支架再狭窄
Keywords:
Drug-eluting stents Percutaneous coronary intervention In-stent restenosis
分类号:
R541.4; R815
DOI:
10.16806/j.cnki.issn.1004-3934.2016.04.006
文献标志码:
A
摘要:
药物洗脱支架的出现虽然明显降低再狭窄率; 但是支架内再狭窄依然是一个重要的临床问题。最近,针对支架内再狭窄出现了很多新的治疗方案。现综述最近的临床数据和治疗进展,用以帮助临床决定裸支架和药物洗脱支架相关的再狭窄的治疗策略。
Abstract:
Although drug-eluting stents have drastically reduced the incidence of in-stent restenosis,it remains a highly significant clinical problem. Recently many new therapeutic options regarding this phenomenon have occurred. In this paper, we systematically reviewed the clinical trial data and treatment advances for helping to decide which therapeutic options related to bare-eluting stents and drug-eluting stents should be chosen.

参考文献/References:

[1] Takeshi T,Kazushige K,Seiji H, et al.The incidence of peri-stent contrast staining after paclitaxel-coated balloon dilatation for in-stent restenosis lesions: a comparison with drug-eluting stent[J].J Am Coll Cardiol,2014,63(12 Suppl): 1A1884.
[2] Cassese S,Byrne RA,Tada T,et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography[J]. Heart,2013,100(2):153-159.
[3] Hara H,Aoki J,Tanabe K, et al. Incidence and predictors for late target lesion revascularization after sirolimus-eluting stent implantation[J]. Circ J, 2013,77:988-994.
[4] Hoppmann P, Koch W, Laugwitz KL, et al. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents[J]. Coron Artery Dis,2014,25(8):658-664.
[5] Dangas GD, Claessen BE, Caixeta A,et al. In-Stent restenosis in the drug-eluting stent era[J]. J Am Coll Cardiol,2010,56(23):1897-1907.
[6] Minha S, Pichard AD, Waksman R,et al. In-stent restenosis of drug-eluting stents[J]. Future Cardiol,2013,9(5):721-731.
[7] Strauss BH.Diabetic patients receiving bare-metal stents:no option patients? [J]. J Am Coll Cardiol,2013,61(16):1686-1687.
[8] Mavromatis K, Samady H, King SB. Revascularization in patients with diabetes: PCI or CABG or none at all[J]. Curr Cardiol Rep,2015,17(3):565.
[9] Tocci G, Barbato E, Coluccia R,et al. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis[J]. Am J Hypertens,2016,29(4):509-518.
[10] Taniwaki M, Stefanini GG, Silber S,et al. 4-Year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents:a report from the RESOLUTE All-Comers Trial(A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)[J]. J Am Coll Cardiol,2014, 63(16):1617-1625.
[11] Hu RT, Liu J, Zhou Y, et al.Association of smoking with restenosis and major adverse cardiac events after coronary stenting: a meta-analysis[J].Pak J Med Sci,2015, 31(4):1002-1008.
[12] Wihanda D, Alwi I, Yamin M, et al.Factors associated with in-stent restenosis in patients following percutaneous coronary intervention[J].Acta Med Indones,2015, 47(3):209-215.
[13] Chakravarty T, White AJ, Buch M,et al. Meta-analysis of incidence, clinical characteristics and implications of stent fracture[J].Am J Cardiol,2010, 106(8):1075-1080.
[14] Cho S, Shin DH, Kim JS,et al. Rationale and design: impact of intravascular ultrasound guidance on long-term clinical outcomes of everolimus-eluting stents in long coronary lesions[J]. Contemp Clin Trials,2015,40:90-94.
[15] Ko YG, Kim JS, Kim BK, et al.Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents(from the Korean DES ISR multicenter registry study [KISS])[J].Am J Cardiol,2012,109(5):607-613.
[16] Alfonso F, Pérez-Vizcayno MJ, Gómez-Recio M, et al.Implications of the “watermelon seeding” phenomenon during coronary interventions for in-stent restenosis[J].Catheter Cardiovasc Interv,2005,66(4):521-527.
[17] Kong J, Hou J, Ma L, et al.Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis[J]. Arch Cardiovasc Dis,2013, 106(2):79-85.
[18] Ozaki Y, Lemos PA, Yamaguchi T,et al.A quantitative coronary angiography-matched comparison between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial(REDUCE Ⅲ)and the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital(RESEARCH)study[J].EuroIntervention,2010,6(3):400-406.
[19] Park SJ, Kim KH, Oh IY,et al. Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents[J].Circ J,2010,74(9):1837-1845.
[20] Seabra Gomes R, de Araújo Gonçalves P, Campante Teles R,et al.Late results(>10 years)of intracoronary beta brachytherapy for diffuse in-stent restenosis[J].Rev Port Cardiol,2014,33(10):609-616.
[21] Oliver LN, Buttner PG, Hobson H, et al.A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis[J].Int J Cardiol,2008,126(2):216-223.
[22] Maluenda G, Ben-Dor I, Gaglia MA Jr, et al.Clinical outcomes and treatment after drug-eluting stent failure:the absence of traditional risk factors for in-stent restenosis[J].Circ Cardiovasc Interv,2012,5(1):12-19.
[23] Yoshida T, Sakata K, Nitta Y, et al.Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries[J].Heart Vessels,2016,31(5):635-642.
[24] Almalla M, Pross V, Marx N, et al.Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis[J].Coron Artery Dis,2012,23(7):492-496.
[25] Latib A, Mussardo M, Ielasi A, et al.Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis[J].JACC Cardiovasc Interv,2011,4(2):155-164.
[26] Alfonso F, Pérez-Vizcayno MJ, Dutary J, et al.Implantation of a drug-eluting stent with a different drug(switch strategy)in patients with drug-eluting stent restenosis. Results from a prospective multicenter study(RIBS Ⅲ [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent])[J].JACC Cardiovasc Interv,2012,5(7):728-737.
[27] Nojima Y, Yasuoka Y, Kume K,et al.Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis[J].Coron Artery Dis,2014,25(8):638-644.
[28] Kawata M, Kato Y, Takada H, et al.Successful rotational atherectomy for a repetitive restenosis lesion with underexpansion of double layer drug-eluting stents due to heavily calcified plaque[J].Cardiovasc Interv Ther,2016,31(1):65-69.
[29] Lee JM, Park J, Kang J,et al.Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials[J].JACC Cardiovasc Interv,2015,8(3):382-394.
[30] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al.A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial(Restenosis Intra-stent of Bare Metal Stents: paclitaxel-elutingballoon vs. everolimus-eluting stent)[J].J Am Coll Cardiol,2014,63(14):1378-1386.
[31] Byrne RA, Neumann FJ, Mehilli J, et al.Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent(ISAR-DESIRE 3): a randomised, open-label trial[J].Lancet,2013,381(9865):461-467.
[32] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial[J].J Am Coll Cardiol,2015,66(1):23-33.

相似文献/References:

[1]陆鑫 张华.无载体含药物洗脱支架研究进展1[J].心血管病学进展,2019,(7):1032.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.017]
 LU xinZHANG Hua.Polymer-free Drug-eluting Stent[J].Advances in Cardiovascular Diseases,2019,(4):1032.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.017]
[2]陈彭辉 李军山 何晋.血管内超声指导冠状动脉复杂病变的介入治疗进展[J].心血管病学进展,2020,(11):1140.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
 CHEN Penghui,LI Junshan,HE Jin.Interventional Therapy for Complex Coronary Artery Lesions Guided by Intravascular Ultrasound[J].Advances in Cardiovascular Diseases,2020,(4):1140.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[3]牛梦瑶 胡晓惠 张静.冠状动脉小血管病变中药物球囊的应用进展[J].心血管病学进展,2022,(1):68.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.018]
 NIU Mengyao,HU Xiaohui,ZHANG Jing.Application of Drug Balloon in Coronary Small Vessel Disease[J].Advances in Cardiovascular Diseases,2022,(4):68.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.018]
[4]赵代鑫?胡晓军?谭巨浪?裴畅.基于Meta分析对比药物涂层球囊与药物洗脱支架在细小冠状动脉疾病中的应用[J].心血管病学进展,2022,(1):82.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.021]
 ZHAO Daixin,HU Xiaojun,TAN Julang,et al.Comparison of Application of Drug-Coated Balloon and Drug-Eluting Stent in Small Coronary Artery Disease Based on Meta Analysis[J].Advances in Cardiovascular Diseases,2022,(4):82.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.021]
[5]袁晓航 冯欢欢 高磊.复发性支架内再狭窄的研究进展[J].心血管病学进展,2022,(8):677.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.002]
 YUAN Xiaohang FENG Huanhuan GAO Lei.Recurrent In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(4):677.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.002]
[6]徐怡 农家聪 郭雅洁 许田 尤威 吴向起 吴志明 孟培娜 贾海波 叶飞.药物洗脱支架植入术后边缘效应的研究进展[J].心血管病学进展,2022,(12):1083.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.006]
 XU Yi,NONG Jiacong,GUO Yajie,et al.Edge Effect After Drug Eluting Stenting[J].Advances in Cardiovascular Diseases,2022,(4):1083.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.006]
[7]周昌颐 王瑞 沈雳.血管支架植入对血管平滑肌细胞的影响[J].心血管病学进展,2023,(4):299.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.003]
 ZHOU Changyi,WANG Rui,SHEN Li.Impact of Vascular Stent Implantation on Vascular Smooth Muscle Cells[J].Advances in Cardiovascular Diseases,2023,(4):299.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.003]
[8]刘玉莹,杨斌.PCI术后损伤血管再内皮化延迟的机制与治疗研究综述[J].心血管病学进展,2024,(3):248.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.013]
 LIU Yuying,YANG Bin.A Review of the mechanism and therapy of delayed re-endothelialization of injured vessels after PCI[J].Advances in Cardiovascular Diseases,2024,(4):248.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.013]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金面上项目(81470486) 作者简介:何晨(1985—),主治医师,博士,主要从事冠心病研究。Email:hchc@163.com 通信作者:袁晋青(1962—),主任医师,博士,主要从事冠心病研究。Email: jqyuan29007@sina.com
更新日期/Last Update: 2016-07-25